Monday, December 19, 2016 6:25:24 PM
Remember this ""Ms. Howson served previously as Senior Vice President of Corporate and Business Development at both SmithKline Beecham (now GSK) and Bristol-Myers Squibb as well as high-level positions at multiple other industry leaders. She has helped companies navigate external alliances, license negotiations, mergers and acquisitions, and venture capital investments. In 1999, she was awarded Healthcare Businesswomen’s Association’s “Woman of the Year” award."
Gilead up .30 today GILD NASDAQ $74.40
"ContraVir Expands Phase 2a Trial of Tenofovir Exalidex (Formerly CMX157) to Include Doses above 100 mg
Tenofovir Exalidex (TXL™) continues to Exhibit Increased Antiviral Activity and Excellent Safety Profile at Doses ranging to 100 mg in HBV Trial
EDISON, N.J., Dec. 19, 2016 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on development and commercialization of targeted antiviral therapies, today announced that tenofovir exalidex (formerly called CMX157), the Company's potent prodrug analog of tenofovir, exhibited increased antiviral activity at the highest planned dose of 100 mg in the ongoing Phase 2a multiple ascending-dose clinical trial of tenofovir exalidex (TXL) in patients with HBV.
This head-to-head trial comparing TXL to tenofovir disoproxil fumarate (TDF, Gilead's Viread®) is the first evaluation of TXL in chronically infected hepatitis B (HBV) patients.
ContraVir plans to begin evaluating TXL at 150 mg per day dosing and potentially higher dosing based on TXL's continued strong performance, to date, and following recent clearance by the independent data safety monitoring board (DSMB).
"We are pleased with the antiviral profile that is being exhibited by TXL at this first stage in our clinical evaluation of this drug in HBV patients," said James Sapirstein, CEO of ContraVir. "TXL has shown an excellent safety profile, and we are encouraged that as we go to higher doses above 100 mg we may see even greater antiviral activity with a continued excellent safety profile.We believe demonstrating this unique profile for TXL may open many doors in terms of developing new combination therapies for HBV that have curative potential."
TXL Phase 2a Clinical Trial Design
The Phase 2a multiple ascending-dose clinical trial is designed to enroll 84 treatment-naïve patients with chronic HBV infection, and to compare TXL to TDF (Viread®). The sequential dose escalation format consists of 10 patients per cohort receiving four weeks of a once-daily dose of 5, 10, 25, 50, 100, 150 and 200 mg, respectively, of TXL, plus two patients per cohort receiving 300 mg of TDF, the standard therapeutic dose of Viread®.
About TXL
Tenofovir Exalidex (TXL) is a highly potent analog of the successful antiviral drug tenofovir. Its novel liver-targeting structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. TXL previously completed a Phase 1b dose escalation clinical trial conducted in healthy volunteers, in which participants were treated at doses up to 100 mg per day for 14 days, displaying an excellent safety, tolerability, and drug distribution profile. Based on TXL's best-in-class potential, ContraVir believes TXL can become the cornerstone of a curative combination therapy for hepatitis B.
TXL™ is a trademark of ContraVir Pharmaceuticals, Inc.
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action: tenofovir exalidex (TXL), a highly potent analog of the successful antiviral drug tenofovir, currently in a Phase 2a trial in HBV patients; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing valnivudine (formerly FV-100), an orally available nucleoside analogue prodrug for the treatment of shingles, which is currently in a Phase 3 clinical trial in shingles patients. Valnivudine earlier demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For more information on contraVir visit, www.contravir.com."
http://ir.contravir.com/2016-12-19-ContraVir-Expands-Phase-2a-Trial-of-Tenofovir-Exalidex-Formerly-CMX157-to-Include-Doses-above-100-mg
If you are going to panic,then you need to panic quickly.
Panda Lun Lun gave birth to her second set of twins on September 3!
Live Baby Panda Cam
http://www.zooatlanta.org/1212/panda_cam
Recent HEPA News
- Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger • GlobeNewswire Inc. • 09/04/2024 01:25:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/07/2024 01:08:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 01:04:30 PM
- Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement • GlobeNewswire Inc. • 07/22/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/21/2024 09:08:39 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:46:12 PM
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial • GlobeNewswire Inc. • 04/19/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 02:02:26 PM
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:57 PM
- Hepion Pharmaceuticals to Present at NASH-TAG 2024 • GlobeNewswire Inc. • 01/03/2024 10:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:30:24 PM
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit • GlobeNewswire Inc. • 11/28/2023 09:15:00 PM
- Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat • GlobeNewswire Inc. • 11/10/2023 01:50:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/09/2023 05:15:08 AM
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model • GlobeNewswire Inc. • 10/25/2023 12:30:00 PM
- Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules • GlobeNewswire Inc. • 09/29/2023 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM